Patents
Literature
9 results about "Treatment-resistant depression" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Treatment-resistant depression (TRD) is a term used in clinical psychiatry to describe a condition that affects people with major depressive disorder (MDD) who do not respond adequately to a course of appropriate antidepressant medication within a certain time. Typical definitions of TRD vary, and they do not include a resistance to psychological therapies. Inadequate response has traditionally been defined as no clinical response whatsoever (e.g. no improvement in depressive symptoms). However, many clinicians consider a response inadequate if the person does not achieve full remission of symptoms. People with treatment-resistant depression who do not adequately respond to antidepressant treatment are sometimes referred to as pseudoresistant. Some factors that contribute to inadequate treatment are: early discontinuation of treatment, insufficient dosage of medication, patient noncompliance, misdiagnosis, and concurrent psychiatric disorders. Cases of treatment-resistant depression may also be referred to by which medications people with TRD are resistant to (e.g.: SSRI-resistant). In TRD adding further treatments such as psychotherapy, lithium, or aripiprazole is weakly supported as of 2019.
Antidepressant compound 4-methyl-6-methoxycoumarin
PendingCN121754531ANervous disorderHeterocyclic compound active ingredientsTherapeutic effectSleep wake
The invention relates to an anti-depression compound 4-methyl-6-methoxy coumarin, and belongs to the technical field of biological medicines. Depression is the most common mental disorder in the world and is also a main reason for disability. The development of a novel anti-depression drug which is based on a nerve plasticity mechanism, takes effect quickly, has a lasting curative effect and is high in safety, and particularly has important clinical requirements and technical necessity for an effective treatment means for refractory depression. Traditional Chinese medicine monomers and a per2- / -zebra fish depression model are adopted for anti-depression drug screening, and finally it is found that 10 mM of 4-methyl-6-methoxycoumarin has the anti-depression characteristic and has the positive treatment effect on the exploration behavior, social interaction and sleep-awakening period of per2- / -zebra fish. The method can effectively rescue and reverse depression-like phenotypes observed in a per2- / -zebra fish circadian rhythmic depression model, and can restore the balance of important gene expression.
Owner:SUZHOU UNIV
Induction regimen for administering 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
The present invention relates to a dosing regimen of 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one, also known as ketamine, or a derivative thereof for use in the treatment of depression, in particular treatment resistant depression.
Owner:HMNC HOLDINGS
Monoacylglycerol Lipase Modulators
Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions.Wherein R1, R2, R2a, R3, R3a, R4, and R4a are defined herein.
Owner:JANSSEN PHARMA NV
Treatment for refractory depression with glycyrrhizin
Owner:MURCK HARALD WESTFIELD
Bupropion dosage forms with reduced food and alcohol dosing effects
This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.
Owner:ANTECIP BIOVENTURES II LLC
Use of pharmaceutical composition
PCT designated stageWO2026052068A1Organic active ingredientsNervous disorderPharmaceutical drugPharmaceutical Substances
The present disclosure relates to use of a pharmaceutical composition. Specifically, the pharmaceutical composition provided by the present disclosure is used for treating inflammatory depression, wherein the pharmaceutical composition comprises: (i) dextromethorphan or a salt of dextromethorphan and (ii) celecoxib or a salt of celecoxib. The pharmaceutical composition of the present disclosure is directed to inflammatory depression (especially inflammatory treatment-resistant depression and anhedonia depression).
Owner:PRECISION BRAIN SCIENCE BIOTECHNOLOGY (SUZHOU) CO LTD
A synergistic neuromodulation system for treatment-resistant depression
The application discloses a kind of synergic neuromodulation systems for refractory depression, it is related to neuromodulation technical field, including: obtaining individual historical conversation data to establish reference quantity, collect cortical physiology and salivary cortisol data to calculate cortical inhibition proxy quantity and axis drive proxy quantity;The above proxy quantity is standardized based on individual reference quantity and generates continuous flip point intensity;According to flip point intensity, the total stimulation load benchmark is continuously distributed as cortical stimulation component load and vagus-related regulation component load, and each component load is mapped into synergic control instruction to drive equipment to execute stimulation.The application quantifies physiological state and adaptively distributes load, avoids the reversal of stimulation effect under specific state, and improves treatment stability.
Owner:樊亚会
Bupropion dosage forms with reduced food and alcohol dosing effects
This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.
Owner:ANTECIP BIOVENTURES II LLC
Monoacylglycerol lipase modulators
Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions.Wherein R1, R2, R2a, R3, R3a, R4, and R4a are defined herein.
Owner:JANSSEN PHARMA NV